<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Invest</journal-id><journal-id journal-id-type="publisher-id">J Clin Invest</journal-id><journal-title-group><journal-title>The Journal of Clinical Investigation</journal-title></journal-title-group><issn pub-type="ppub">0021-9738</issn><issn pub-type="epub">1558-8238</issn><publisher><publisher-name>American Society for Clinical Investigation</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39666384</article-id><article-id pub-id-type="pmc">PMC11785915</article-id><article-id pub-id-type="publisher-id">178528</article-id><article-id pub-id-type="doi">10.1172/JCI178528</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>A deep intronic mutation causes RAD50 deficiency through an unusual mechanism of distant exon activation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bousset</surname><given-names>Kristine</given-names></name><email>kristine.bousset@mh-hannover.de</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Donega</surname><given-names>Stefano</given-names></name><email>stefano.donega@nih.gov</email><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ameziane</surname><given-names>Najim</given-names></name><email>n.ameziane@vumc.nl</email><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Fleischhammer</surname><given-names>Tabea</given-names></name><email>fleischhammer@iftc.uni-hannover.de</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramachandran</surname><given-names>Dhanya</given-names></name><email>ramachandran.dhanya@mh-hannover.de</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Poley-Gil</surname><given-names>Miriam</given-names></name><email>miriampol2c@gmail.com</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Schindler</surname><given-names>Detlev</given-names></name><email>schindler@biozentrum.uni-wuerzburg.de</email><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>van de Laar</surname><given-names>Ingrid M.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Pagani</surname><given-names>Franco</given-names></name><email>pagani@icgeb.org</email><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>D&#x000f6;rk</surname><given-names>Thilo</given-names></name><email>doerk.thilo@mh-hannover.de</email><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Gynecology Research Unit, Hannover Medical School, Hannover, Germany.</aff><aff id="A2"><label>2</label>International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, and Intramural Research Program of National Institute on Aging, NIH, Baltimore, Maryland, USA.</aff><aff id="A3"><label>3</label>UMC Cancer Center, Amsterdam, Netherlands.</aff><aff id="A4"><label>4</label>Institute of Human Genetics, University of W&#x000fc;rzburg, W&#x000fc;rzburg, Germany.</aff><aff id="A5"><label>5</label>Department of Clinical Genetics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands.</aff><author-notes><corresp>Address correspondence to: Thilo D&#x000f6;rk, Hannover Medical School, Gynecology Research Unit, D-30625 Hannover, Germany. Email: <email>doerk.thilo@mh-hannover.de</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2024-12-12T12:00:00-0500"><day>12</day><month>12</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic" iso-8601-date="2025-02-03T12:00:00-0500"><day>3</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>12</month><year>2024</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>135</volume><issue>3</issue><elocation-id>e178528</elocation-id><permissions><copyright-statement>&#x000a9; 2024 Bousset et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Bousset et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xlink:href="https://www.jci.org/articles/view/178528">This article is available online at https://www.jci.org/articles/view/178528</self-uri><abstract abstract-type="toc"><p>This study identifies and characterizes a novel type of splicing mutation in RAD50 deficiency, a rare genetic disorder.</p></abstract><kwd-group kwd-group-type="specialties"><kwd>Cell biology</kwd><kwd>Genetics</kwd></kwd-group><kwd-group kwd-group-type="keywords"><kwd>DNA repair</kwd><kwd>Genetic diseases</kwd><kwd>RNA processing</kwd></kwd-group></article-meta></front><body><p><bold>To the editor:</bold> Human RAD50 deficiency is a very rare genomic instability syndrome associated with microcephaly and stunted growth (<xref rid="B1" ref-type="bibr">1</xref>). Here, we describe RAD50 deficiency in two siblings harboring a far-intronic <italic toggle="yes">RAD50</italic> 5 bp deletion (&#x00394;5) in trans with a classic frameshift variant. The &#x00394;5 mutation did not affect canonical splice sites but activated a poison 87 bp exon 30 nucleotides downstream. In the following, we provide evidence that this unusual pathogenic variant overcomes two blocking mechanisms to activate exon inclusion from a distance and a splice-switching strategy leads to effective correction.</p><p>Two siblings were diagnosed with clinical hallmarks of RAD50 deficiency at the Erasmus MC (<xref rid="sd" ref-type="sec">Supplemental Methods</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 1A</xref>; supplemental material available online with this article; <ext-link xlink:href="https://doi.org/10.1172/JCI178528DS1" ext-link-type="uri">https://doi.org/10.1172/JCI178528DS1</ext-link>). Genomic DNA sequencing of all RAD50 coding exons revealed heterozygosity for frameshift insertion c.2157_2158insT in both patients and their mother, and the RAD50 protein was almost absent in patient fibroblasts (<xref rid="F1" ref-type="fig">Figure 1A</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 1B</xref>). Subsequent <italic toggle="yes">RAD50</italic> cDNA sequencing revealed an unexpected 87-nucleotide insertion arising from intron 21 that preserved the reading frame while introducing a premature stop codon (<xref rid="F1" ref-type="fig">Figure 1A</xref>). Surprisingly, no nucleotides immediately flanking this poison exon were mutated. Instead, we identified a TGAGT deletion (c.3390-1119_3390-1115del, NC_000005.10:g.132635996_132636000del) 30&#x02013;34 nucleotides upstream of the cryptic acceptor site in both siblings and their father (<xref rid="F1" ref-type="fig">Figure 1A</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 1B</xref>). This suggested a noncanonical activation mechanism for the poison exon.</p><p>We designed a <italic toggle="yes">RAD50</italic> minigene construct to investigate how the &#x00394;5 variant promotes exon inclusion (<xref rid="sd" ref-type="sec">Supplemental Methods</xref>). Splicing pattern analysis by RT-PCR revealed that exon 21 was spliced to exon 22 for WT sequence, whereas the 5-nucleotide deletion resulted in poison exon inclusion (<xref rid="F1" ref-type="fig">Figure 1B</xref>). This observation also held true when the <italic toggle="yes">RAD50</italic> sequence was placed into the context of a hybrid F9 minigene (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>) (<xref rid="B2" ref-type="bibr">2</xref>). These results established a causative role of the distant deletion for the splicing defect.</p><p>For mechanistic understanding, we performed site-directed mutagenesis of the TGAGT sequence (<xref rid="F1" ref-type="fig">Figure 1C</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>). Any 3- or 4-base deletion activated the poison exon (<xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>). Single-base deletion of either A or G in positions 3 and 4 mimicked deletion of the entire element, while deletion of other bases induced only partial exon inclusion (<xref rid="F1" ref-type="fig">Figure 1C</xref>). It made a difference whether GA or AG was retained (Del2 versus Del4), consistent with an AG-exclusion zone (AGEZ) (<xref rid="B3" ref-type="bibr">3</xref>). Among single-base substitutions, the strongest exon activation occurred when transverting positions 3 and 4 to pyrimidines while purine transitions showed attenuated effects (<xref rid="F1" ref-type="fig">Figure 1C</xref>). Thus, although the AG dinucleotide seemed important in repressing the poison exon, additional elements contributed to the final block. This was further supported by the observation that the Del1,2 deletion induced exon activation up to approximately 50%, despite the presence of the AG dinucleotide (<xref rid="F1" ref-type="fig">Figure 1C</xref>). As the most deleterious point mutations created pyrimidines, we next considered whether polypyrimidine tract (PPT) strengthening might contribute to exon activation, possibly through binding of splicing factors.</p><p>Two pyrimidine-rich sequences flank the TGAGT element. We observed significantly (<italic toggle="yes">P</italic> &#x0003c; 0.0001, unpaired <italic toggle="yes">t</italic> test, 2 degrees of freedom) more exon inclusion in minigene constructs bringing these imperfect pyrimidine stretches closer together, with less than 3 separating purines, although an AG partially suppressed this effect (<xref rid="F1" ref-type="fig">Figure 1D</xref>). We evaluated the contribution of either imperfect PPT in separate mutagenesis experiments (<xref rid="F1" ref-type="fig">Figure 1E</xref>). An enrichment of thymidines empowered the downstream PPT and activated poison exon inclusion despite the presence of the TGAGT element (3&#x02032;-splice site&#x02013;improved [3&#x02032;ss-improved] construct, <xref rid="F1" ref-type="fig">Figure 1E</xref>). Deletion of the upstream pyrimidine-rich sequence was neutral on the WT background (&#x00394;TTTAT-WT) but reverted the effect of the original &#x00394;5 deletion (&#x00394;TTTAT-&#x00394;5) (<xref rid="F1" ref-type="fig">Figure 1E</xref>). Thus, distant exon activation required upstream pyrimidines to overcome a poor downstream PPT.</p><p>We then analyzed 11 factors known to affect 3&#x02032;ss recognition in minigene cotransfection experiments. U2AF35 and U2AF65 strongly induced exon inclusion (<xref rid="F1" ref-type="fig">Figure 1F</xref>). In vitro binding experiments with biotinylated RNA oligonucleotides and nuclear extracts indicated increased binding of U2AF65 to the &#x00394;5 mutant and to a &#x00394;3(GAG) core mutant RNA (<xref rid="F1" ref-type="fig">Figure 1G</xref>). Thus, the most conceivable mechanism by which the &#x00394;5 deletion promotes the aberrant 3&#x02032;ss is by improving the affinity of the PPT to U2AF65 (<xref rid="F1" ref-type="fig">Figure 1H</xref>).</p><p>To test functional correction strategies, we generated a large-T immortalized cell line from patient skin fibroblasts (F601-T). Like primary fibroblasts, F601-T cells expressed very low levels of RAD50 (<xref rid="F1" ref-type="fig">Figure 1I</xref>). Complementation with WT <italic toggle="yes">RAD50</italic> (<xref rid="B4" ref-type="bibr">4</xref>) restored RAD50 and NBN protein levels and normalized radiation-induced phosphorylation of KAP1 and CHEK2 at ATM target sites (<xref rid="sd" ref-type="sec">Supplemental Figure 4</xref>). We tested whether RAD50 levels could also be restored through targeted splicing correction with antisense morpholino oligonucleotides (AMOs). AMOs against either canonical splice site of the poison exon effectively suppressed exon inclusion (<xref rid="F1" ref-type="fig">Figure 1I</xref>). Importantly, RAD50 protein levels and ATM kinase activity were restored, providing functional evidence of the AMO efficacy (<xref rid="F1" ref-type="fig">Figure 1I</xref>) and suggesting a potential therapeutic strategy (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>In conclusion, a far-intronic deletion in <italic toggle="yes">RAD50</italic> can cause disease through activation of an exon 30 nucleotides apart from the mutation site. Activating mutations generated a composite pyrimidine-rich sequence with increased U2AF binding. Exon inclusion required the shortening of an insulating stretch of 3 purines and was partly prevented by a residual AG dinucleotide. AMO-mediated splice switching fully restored normal RAD50 expression in patient-derived fibroblasts. Our findings help to characterize human RAD50 deficiency and uncover an unusual splicing mutational mechanism with potential relevance for other human genetic diseases.</p><sec sec-type="supplementary-material" id="sd"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><caption><title>Supplemental data</title></caption><media xlink:href="jci-135-178528-s117.pdf" id="d67e296" position="anchor"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data"><caption><title>Unedited blot and gel images</title></caption><media xlink:href="jci-135-178528-s118.pdf" id="d67e300" position="anchor"/></supplementary-material><supplementary-material id="SD3" position="float" content-type="local-data"><caption><title>Supporting data values</title></caption><media xlink:href="jci-135-178528-s119.xlsx" id="d67e304" position="anchor"/></supplementary-material></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p></fn><fn><p><bold>Copyright:</bold> &#x000a9; 2024, Bousset et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p></fn><fn><p><bold>Reference information:</bold><italic toggle="yes"> J Clin Invest</italic>. 2025;135(3):e178528. https://doi.org/10.1172/JCI178528.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waltes</surname><given-names>R</given-names></name>
<etal>et al</etal>
</person-group><article-title>Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder</article-title><source>Am J Hum Genet</source><year>2009</year><volume>84</volume><issue>5</issue><fpage>605</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.04.010</pub-id><!--<pub-id pub-id-type="pmcid">2681000</pub-id>--><pub-id pub-id-type="pmid">19409520</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tajnik</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Molecular basis and therapeutic strategies to rescue factor IX variants that affect splicing and protein function</article-title><source>PLoS Genet</source><year>2016</year><volume>12</volume><issue>5</issue><elocation-id>e1006082</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006082</pub-id><!--<pub-id pub-id-type="pmcid">4882169</pub-id>--><pub-id pub-id-type="pmid">27227676</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wimmer</surname><given-names>K</given-names></name>
<etal>et al</etal>
</person-group><article-title>AG-exclusion zone revisited: lessons to learn from 91 intronic NF1 3&#x02019; splice site mutations outside the canonical AG-dinucleotides</article-title><source>Hum Mutat</source><year>2020</year><volume>41</volume><issue>6</issue><fpage>1145</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1002/humu.24005</pub-id><!--<pub-id pub-id-type="pmcid">7317903</pub-id>--><pub-id pub-id-type="pmid">32126153</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000f6;lkening</surname><given-names>L</given-names></name>
<etal>et al</etal>
</person-group><article-title>RAD50 regulates mitotic progression independent of DNA repair functions</article-title><source>FASEB J</source><year>2020</year><volume>34</volume><issue>2</issue><fpage>2812</fpage><lpage>2820</lpage><pub-id pub-id-type="doi">10.1096/fj.201902318R</pub-id><pub-id pub-id-type="pmid">31908056</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>A framework for individualized splice-switching oligonucleotide therapy</article-title><source>Nature</source><year>2023</year><volume>619</volume><issue>7971</issue><fpage>828</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06277-0</pub-id><!--<pub-id pub-id-type="pmcid">10371869</pub-id>--><pub-id pub-id-type="pmid">37438524</pub-id>
</element-citation></ref></ref-list><notes notes-type="version-changes"><sec sec-type="version-changes"><label>Version 1</label><title>12/12/2024</title><p>In-Press Preview</p></sec><sec sec-type="version-changes"><label>Version 2</label><title>02/03/2025</title><p>Electronic publication</p></sec></notes></back><floats-group><fig position="float" id="F1"><label>Figure 1</label><caption><title>Pathogenic RAD50 splicing mechanism.</title><p>(<bold>A</bold>) Top: Western blot of RAD50 protein (left) and RT-PCR of <italic toggle="yes">RAD50</italic> transcript (right) from control and patient fibroblasts. Bottom: Intron 21 with c.3390-1119_3390-1115del deletion (blue) and downstream poison exon (italics underlined). (<bold>B</bold>&#x02013;<bold>G</bold>) Splicing analysis in HEK293 cells (see <xref rid="sd" ref-type="sec">Supplemental Methods</xref> for additional information). (<bold>B</bold>) <italic toggle="yes">RAD50</italic> minigene constructs confirming exon inclusion for the &#x00394;5 mutant. (<bold>C</bold>) Effects of deletions and substitutions within 5&#x02032;-TGAGT-3&#x02032; on minigene splicing. (<bold>D</bold>) Exon inclusion with short versus long PPTs. Data are shown as the mean &#x000b1; SD. (<bold>E</bold>) Role of pyrimidine-rich sequences for minigene splicing. (<bold>F</bold>) Overexpression of U2AF promotes aberrant splicing. (<bold>G</bold>) In vitro binding of U2AF to RNA oligonucleotides spanning the &#x00394;5 region. (<bold>H</bold>) Model for a role of distal extension of the poly-pyrimidine region in promoting exon inclusion through U2AF accumulation, if devoid of an AG. (<bold>I</bold>) Correction of RAD50 splicing, protein level, and ionizing radiation&#x02013;induced ATM signaling by AMO treatment.</p></caption><graphic xlink:href="jci-135-178528-g116" position="float"/></fig></floats-group></article>